Drugs / GSK3915393
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06625489 | Oct → Nov 2024 | idiopathic pulmonary fibrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04604795 | Nov 2020 → Jun 2021 | celiac disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06317285 | Apr 2024 → Oct 2025 | idiopathic pulmonary fibrosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3915393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06317285 ↗ |
| Route | Oral | “GSK3915393 capsules will be given orally.” NCT04604795 ↗ |